DAX ®13.579,33-0,62%TecDAX ®3.237,15-0,83%Dow Jones29.026,41-0,66%NASDAQ 1009.508,34-1,24%

PRESS RELEASE: Expedeon AG: Expedeon AG and Abcam plc close EUR 120 million transaction

| Quelle: Dow Jones Newsw... | Lesedauer etwa 5 min. | Text vorlesen Stop Pause Fortsetzen

DGAP-News: Expedeon AG / Key word(s): Disposal
Expedeon AG: Expedeon AG and Abcam plc close EUR 120 million transaction
(news with additional features)

2020-01-02 / 07:30
The issuer is solely responsible for the content of this announcement.


*02 January 2020*

*Expedeon AG and Abcam plc close EUR 120 million transaction*

? *Closing triggers payment of EUR 120 million*

? *Expedeon AG plans name change to 4basebio AG and change of ticker to

? *Future focus on DNA manufacturing and enzymes for diagnostics*

*Heidelberg, Germany and Cambridge, UK, 02 January 2020 *- Expedeon AG
(Frankfurt: EXNN; ISIN: DE000A2YN801; Prime Standard) today announced the
closing of the sale and purchase agreement with Abcam plc (London Stock
Exchange: ABC; ISIN: GB00B6774699; AIM MTF), Cambridge, UK, for the sale of
the Company's proteomics and immunology business, as announced on November
11, 2019 and as approved by the Extraordinary Shareholder Meeting on
December 19, 2019. The closing triggers a payment of EUR 120 million by
Abcam to Expedeon, of which EUR 105.6 million is due immediately and EUR
14.4 million will be held in escrow for two years, in accordance with the
terms of the agreement with Abcam.

Expedeon AG will be changing its Company name to 4basebio AG and accordingly
change the ticker symbol to 4BSB following entry in the Commercial Register,
which is expected shortly. The Company's shares will continue to be listed
on the Frankfurt Stock Exchange and the German securities identification
code (WKN) will remain unchanged (A2YN80).

"We are now commencing a new chapter in the Company's development with a new
name, a new business focus and excellent funding resulting from this
transaction. Referring to the four base building blocks of all genetic
material, the new company name 4basebio AG reflects our new DNA-based
business focus. We will also continue with our successful buy & build
strategy," *said Dr. Heikki Lanckriet, CEO of Expedeon AG*.

Under its future name 4basebio, Expedeon will focus activities in the field
of genomics, building on the expertise in its Spanish business unit,
Expedeon S.L.U. (Madrid, Spain). The Company will focus on DNA manufacturing
to supply DNA products for therapeutic and other uses requiring large
amounts of high-purity DNA, such as the fast-growing market of novel gene
therapies and gene vaccines.

The high need for DNA caused by wide adoption of gene therapies and gene
vaccines is expected to drive the synthetic biology market to $38.7 billion
by 2020 with an annual growth rate (CAGR) of 44.2 %. Besides DNA
manufacturing, 4basebio aims at providing research and diagnostic products
based on its RNA reverse transcriptase, DNA polymerase and DNA primase
enzymes, addressing the research tools and diagnostic products markets. The
reverse transcriptases market currently has an annual turnover of USD 280
million. The isothermal DNA amplification market segment had a 2015 value of
USD 266 million and a CAGR of 13.5 %.

*For further information, please contact:*

*Expedeon AG*

Dr. Heikki Lanckriet
Phone: +44 1223 873 364
Email: heikki.lanckriet@expedeon.com
Investor website: www.investors.expedeon.com [1]

*MC Services AG (Investor Relations and International Media Relations)*

Raimund Gabriel
Managing Partner
Phone: +49 89 210228 0
Email: expedeon@mc-services.eu

*About Expedeon AG: *www.expedeon.com [2]

Expedeon is an enabler of exciting advances in medical science and patient
care. The Company's core technologies, innovative products and services are
used in research laboratories around the world, enabling scientists to push
the boundaries of research and product development, and play an integral
part in new diagnostic tools being brought to market. After selling the
proteomics and immunology business, Expedeon AG will focus on manufacturing
highly pure DNA for use in gene therapies and gene vaccines. Expedeon AG has
offices in Germany, Spain, UK, and the US. The Company is listed on the
Prime Standard segment of the Frankfurt Stock Exchange (Ticker: EXNN; ISIN:

### This publication is intended for information only and constitutes
neither an offer to sell nor an invitation to buy securities. Some
statements included in this press release, relating neither to proven
financial results nor other historical data, should be viewed as
forward-looking, i.e. not definite. Such statements are mainly predictions
of future results, trends, plans or goals. These statements should not be
considered to be total guarantees since given their very nature they are
subject to known and unknown risks and imponderability and can be affected
by other factors as a consequence of which the actual results, plans and
goals of Expedeon AG may deviate greatly from the established conclusions or
implied predictions contained in such statements. Expedeon does not
undertake to publicly update or revise these statements in the light of new
information or future results or for any other reason. ###

Additional features:

Document: http://n.eqs.com/c/fncls.ssp?u=CXBIEFSVAJ [3]
Document title: Abcam_Eng

2020-01-02 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: Expedeon AG
Waldhofer Str. 102
69123 Heidelberg
Phone: +49 (0) 6221 3540 125
Fax: +49 (0) 6221 3540 127
E-mail: investors@expedeon.com
Internet: www.expedeon.com
ISIN: DE000A2YN801
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich,
Stuttgart, Tradegate Exchange
EQS News ID: 945259

End of News DGAP News Service

945259 2020-01-02

1: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=511ce11eab4f3fc5096a4f05c8d41b9f&application_id=945259&site_id=vwd&application_name=news
2: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=5742c444e02edea7ee94446b3dc13b3a&application_id=945259&site_id=vwd&application_name=news
3: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=1d89e0d1fcddc7b942d4e6a176dc1fbd&application_id=945259&site_id=vwd&application_name=news

(END) Dow Jones Newswires

January 02, 2020 01:30 ET ( 06:30 GMT)

Das könnte Sie auch interessieren



Aktuelle Videos

HSBC Trading TV



Börsen & Märkte


zur Mediathek

Diese Seite empfehlenschliessen
Interessant, oder?
Teilen Sie diese Seite auf Facebook oder Twitter
Wenn Sie auf die Teilen-Buttons klicken und sich bei den Betreibern einloggen, werden Daten an den jeweiligen Betreiber übermittelt. Bitte beachten Sie die Datenschutzerklärung.
Aktuelle Umfrageschliessen
Schleswig-Holstein fordert ein komplettes Rauchverbot in der Öffentlichkeit. Sollte ein Rauchverbot auch an öffentlichen Plätzen gelten?
Jetzt abstimmen!
Alle Umfragen ansehen